Glybera (Alipogene tiparvovec)


DRUG (BRAND / GENERIC): Glybera / alipogene tiparvovec
THERAPY CLASS: Gene therapy
CURRENT INDICATION: Lipoprotein Lipase Deficiency (LPLD)

Strength: 3 x 10¹² gc/ml
Pharmaceutical form: Solution for injection
Immediate Packaging: vial (glass)
Content: 1 ml
Pack size: Each patient-specific pack
contains a sufficient amount of
vials to dose each patient with 1
x 1012 gc/kg bodyweight




Buy Glybera Online – (Alipogene tiparvovec)

Buy Glybera online (alipogene tiparvovec) is a gene therapy indicated for the treatment Lipoprotein Lipase Deficiency (LPLD). It was developed by Amsterdam Molecular Therapeutics (AMT), which was acquired by uniQure in April 2012. In October 2012, uniQure received marketing authorisation approval for Glybera from the European Commission (EC) for treating patients with LPLD who have chronic and acute pancreatitis attacks. Glybera is the first gene therapy to be licensed in Europe. Alipogene tiparvovec (marketed under the trade name Glybera) is a gene therapy treatment, developed and marketed by uniQure N.V., that compensates for lipoprotein lipase deficiency (LPLD), a rare inherited disorder which can cause severe pancreatitis. In July 2012, the European Medicines Agency recommended it for approval, the first recommendation for a gene therapy treatment in either Europe or the United States. The recommendation was endorsed by the European Commission in November 2012 to make the process of Buy Glybera Online legal worldwide.


Lipoprotein Lipase Deficiency (LPLD)

Lipoprotein Lipase Deficiency (LPLD) is rare genetic condition that elevates the levels of fat in the blood. The disease occurs due to alterations in LPL genes, which are responsible for breaking down of a protein-lipid complex called chylomicron. The chylomicron particles play a key role in transporting fat through the blood. The disease results in severe and chronic pancreatitis attacks and also may cause early onset diabetes and cardiovascular complications in some patients. The symptoms of the disease include abdominal pain, and increased risk of pancreatitis. LPLD is very rare as it occurs in one or two in every million people across the world. However, the disease is more common in some regions, including parts of Canada.

Glybera Mechanism of Action (Buy Glybera online)

Glybera contains alipogene tiparvovec as the active substance. The drug works by breaking down the chylomicron particles present in the blood. It delivers a normal LPL gene into the body for correcting the LPL deficiency. The drug normalises the metabolism of fat in the blood and thereby prevents episodes of pancreatitis. The drug is administered in the form of an injection into the leg muscle. If you have been searching for this medication then today is your lucky day as you can now Buy Glybera online without prescription and have it delivered to any destination worldwide.


Clinical trials of Europe’s first approved gene therapy

AMT conducted a Phase II/III clinical study on Glybera between February 2009 and April 2011. It was an open label, single group assignment which enrolled five patients with LPLD. The primary outcome of the study was finding the reduction of triglyceride (TG) concentrations in 12 weeks time. The secondary outcome measures included finding the reduction in chylomicrons, determining the biological activity, and assessing the safety profile of the drug.

A 14-week Phase III open-label clinical study on Glybera was conducted in five LPLD patients from Quebec in Canada. Results of the study were announced in March 2012. The results demonstrated that one-time administration of Buy Glybera online significantly improved chylomicron metabolism after a low-fat meal.


Best Place To Buy Glybera Online –  (Alipogene Tiparvovec) For Sale without prescription

The adeno-associated virus serotype 1 (AAV1) viral vector delivers an intact copy of the human lipoprotein lipase (LPL) gene to muscle cells. The LPL gene is not inserted into the cell’s chromosomes but remains as free floating DNA in the nucleus. The injection is followed by immunosuppressive therapy to prevent immune reactions to the virus. Data from the clinical trials indicates that fat concentrations in blood were reduced between 3 and 12 weeks after injection, in nearly all patients. The advantages of AAV include apparent lack of pathogenicity, delivery to non-dividing cells, and much smaller risk of insertion compared to retroviruses, which show random insertion with accompanying risk of cancer. AAV also presents very low immunogenicity, mainly restricted to generating neutralizing antibodies, and little well defined cytotoxic response. The cloning capacity of the vector is limited to replacement of the virus’s 4.8 kilobase genome.

For inquiries on other products visit our SHOP .


Please follow and like us:


There are no reviews yet.

Be the first to review “Glybera (Alipogene tiparvovec)”

Your email address will not be published. Required fields are marked *